...AND MORE POWER
IF YOU NEED IT
Stephanie: Has ASCVD and
achieved LDL-C reduction
beyond statins1*
PRALUENT is the only PCSK9
inhibitor that offers 2 doses
with 2 levels of efficacy
In COMBO I
44%
58%
LDL-C reduction at
24 weeks on top of statins
starting with PRALUENT 75 mg†
In the LONG TERM Study
T:14”
B:14.25”
S:12.5”
LDL-C reduction at
24 weeks on top of statins
with PRALUENT 150 mg
The recommended starting dose
is 75 mg every 2 weeks1
CLINICAL STUDIES
COMBO I (Study 2) was a multicenter, double-blind, placebo-controlled trial that compared PRALUENT (n=209)
with placebo (n=107). Patients were taking maximally tolerated doses of statins with or without other lipidmodifying therapy, and required additional LDL-C reduction. The mean age was 63 years (range 39-87), 34% were
women, 82% were Caucasian, 16% were Black, and 11% were Hispanic/Latino. Mean baseline LDL-C was 102 mg/dL.
The primary efficacy endpoint, measured at week 24, was the mean percent change in LDL-C from baseline.1
LONG TERM trial (Study 1) was a multicenter, double-blind, placebo-controlled trial that compared PRALUENT
150 mg Q2W (n=1553) with placebo (n=788). The average LDL-C at baseline was 122 mg/dL. The primary efficacy
endpoint, measured at week 24, was the mean percent change in LDL-C from baseline.1
IMPORTANT SAFETY INFORMATION
• Liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with
PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients,
respectively. Increases in serum transaminases to greater than 3 times the
upper limit of normal occurred in 1.7% of patients treated with PRALUENT
and 1.4% of patients treated with placebo
• The most common adverse reactions leading to treatment discontinuation
in patients treated with PRALUENT were allergic reactions (0.6% versus
0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes
(0.3% versus <0.1%)
• PRALUENT is a human monoclonal antibody. As with all therapeutic proteins,
there is a potential for immunogenicity with PRALUENT
Please see brief summary of Prescribing Information on next page.
Learn more at PraluentHCP.com